Evolving Paradigms in the Management and Outcomes of Sarcomatoid Renal Cell Carcinoma in the Era of Immune Checkpoint Inhibitors.

Authors

Ragia Aly
Amandeep S Aujla
Sachin Gupta
Ruby Gupta, Beaumont Health Fellow
Sorab Gupta
Sheila Kalathil

Document Type

Article

Publication Date

10-1-2020

Publication Title

World Journal of Oncology

Abstract

Renal cell carcinoma (RCC) is a common cancer that affects a significant number of patients every year around the world. The presence of sarcomatoid features in these tumors is considered a poor prognostic feature. Patients with RCC with sarcomatoid features had significantly worse outcomes when treated with sunitinib, the previous first-line standard of care therapy when compared to patients without such features. Multiple immune checkpoint inhibitors have recently been approved for the treatment of RCC. In this article, we review the literature available on the outcomes of patients with sarcomatoid RCC treated with immune checkpoint inhibitors.

Volume

11

Issue

5

First Page

183

Last Page

187

Recommended Citation

Aly R, Aujla AS, Gupta S, Gupta R, Gupta S, Kalathil S. Evolving Paradigms in the Management and Outcomes of Sarcomatoid Renal Cell Carcinoma in the Era of Immune Checkpoint Inhibitors. World J Oncol. 2020 Oct;11(5):183-187. doi: 10.14740/wjon1325. Epub 2020 Oct 15. PMID: 33117461; PMCID: PMC7575279.

DOI

10.14740/wjon1325

ISSN

1920-454X

PubMed ID

33117461